Gilead Sciences (GILD) : Todd Asset Management scooped up 91,052 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 9, 2016. The investment management firm now holds a total of 622,897 shares of Gilead Sciences which is valued at $51,513,582.Gilead Sciences makes up approximately 1.59% of Todd Asset Management’s portfolio.
Other Hedge Funds, Including , Stratos Wealth Partners Ltd. boosted its stake in GILD in the latest quarter, The investment management firm added 4,638 additional shares and now holds a total of 30,629 shares of Gilead Sciences which is valued at $2,533,018. Gilead Sciences makes up approx 0.22% of Stratos Wealth Partners Ltd.’s portfolio.Neuberger Berman Group reduced its stake in GILD by selling 143,341 shares or 23.62% in the most recent quarter. The Hedge Fund company now holds 463,489 shares of GILD which is valued at $39,248,249. Gilead Sciences makes up approx 0.05% of Neuberger Berman Group’s portfolio.Hilton Capital Management reduced its stake in GILD by selling 34 shares or 1.05% in the most recent quarter. The Hedge Fund company now holds 3,200 shares of GILD which is valued at $270,976. Gilead Sciences makes up approx 0.09% of Hilton Capital Management’s portfolio.Bank Of The West boosted its stake in GILD in the latest quarter, The investment management firm added 3,354 additional shares and now holds a total of 106,275 shares of Gilead Sciences which is valued at $8,999,367. Gilead Sciences makes up approx 1.25% of Bank Of The West’s portfolio.Calamos Advisors boosted its stake in GILD in the latest quarter, The investment management firm added 13,902 additional shares and now holds a total of 545,722 shares of Gilead Sciences which is valued at $48,138,138. Gilead Sciences makes up approx 0.43% of Calamos Advisors’s portfolio.
Gilead Sciences closed down -0.06 points or -0.07% at $82.7 with 83,32,857 shares getting traded on Friday. Post opening the session at $82.66, the shares hit an intraday low of $82.41 and an intraday high of $83.87 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Gilead Sciences reported $3.03 EPS for the quarter, missing the analyst consensus estimate by $ -0.10 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $3.13. The company had revenue of $7794.00 million for the quarter, compared to analysts expectations of $8065.42 million. The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.94 EPS.
Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Maxim Group to ” Hold” on Apr 29, 2016. Shares were Reiterated by UBS on Apr 29, 2016 to “Buy” and Lowered the Price Target to $ 118 from a previous price target of $130 .Shares were Reiterated by Leerink Partners on Mar 16, 2016 to “Outperform” and Lowered the Price Target to $ 127 from a previous price target of $130 .
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.